Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
- A recent estimate of the annual incidence of traumatic spinal cord injury (CCI) is approximately 54 cases per one million people in the United States.
- The estimated number of people with tSCI living in the United States is approximately 302,000 persons, ranging from 255,000 to 383,000 persons.
- The average age at injury has increased from 29 during the 1970s to 43 since 2015.
- Traumatic brain injury (TBI) is defined as an alteration in brain function or other evidence of brain pathology caused by an external force. Examples of TBI include falls, assaults, motor vehicle accidents and sports injuries.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential for seven years of market exclusivity after approval
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
| Stock stats Jan 5 2024 | |
| 52 Week Range | 0.1000 0.4200 |
| Volume | 7,000 |
| Avg. Volume | 4,511 |
| Market Cap | 14.475M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.01 |
| In-depth Corporate Presentation Litchfield Research |
November 3, 2022
Marc CHALLANDE
If you seek a “10 bagger” through penny stocks on the OTC exchange, you might extend your research. Many stocks have cheap pricing and could look attractive. Still, in some cases, they are just zombie stocks, meaning you would undoubtedly lose money while investors aim to generate a positive return on investment. Besides, we searched through this sea of micro/small-cap companies, a solid ship that could lead you toward a bright horizon. Onboard Pharmagreen Biotech (OTC: PHBI), and let it guide you toward green lands.
Cannabis + Nutraceuticals = Success
Pharmagreen is involved in two sectors poised for growth. Let’s talk about the cannabis sector first. The industry was valued at USD $17.8B in 2021, which is very interesting. The sector’s growth, commonly called Compound Annual Growth Rate, is set to represent 25.3% from 2022 to 2030. Why is this data this high? Cannabis witnesses more and more acceptance from worldwide governments with a high rate of legislation. Cannabis’ benefits aren’t brand new. Throughout history, cannabis has long been used for medicinal purposes but not as the first line of treatment. Nowadays, it is remarkably effective in its ability as therapeutic for chronic pain and treating nausea caused due to chemotherapy. Even if it is still classified as a Schedule I drug by the DEA, more than two-thirds of the states have legalized it, and the FDA has approved medical cannabis in the form of CBD products for epilepsy seizures and, as mentioned above, for nausea.
Now, let’s dive into nutraceuticals. This is a considerable segment worth USD $396B, and even if it grows slower than cannabis, it will still increase by 5.2% between 2022 and 2030. If this word at first glance seems barbaric, many use them as an essential component of consumer lifestyle. Many people undergo metabolic disorders, and it keeps growing worldwide. According to the IDF, more than 30% of the US population is estimated to have metabolic syndrome. This market is divided into functional beverages, foods, and dietary supplements. Out of these three segments, functional foods represented the most significant stake, worth USD $157B in 2021. The demand for this market share will continue to augment as it means several health benefits, including weight management and improved blood circulation. What also helped the sector is its distribution channels. It was first sold through pharmacies, Brick & Mortar stores, and now E-commerce has its word to say. The last segment generated USD $116B. About Covid pandemic positively affected the overall growth of the nutraceuticals industry. Preventative measures against coronavirus promoted the consumption of nutritious and functional foods with high zinc, sodium, vitamin D, vitamin C, and mineral content, escalating the sales of nutraceutical products.
About Pharmagreen
Let’s learn more about Pharmagreen Biotech (OTC: PHBI). Pharmagreen builds a vertically integrated cannabis business in California. The company uses “Chibafreen,” a proprietary tissue culture system ensuring that all plants are disease and pest free while maintaining uniformity from generation to generation. It is also good to mention the farm is vegan and non-spray certified by the count of Mendocino. Thanks to its technology, the company can ensure the cultivation and manufacture of the highest quality craft cannabis products.
The company also welcomed Ethan Styles as VP of product research and development. Ethan Styles has solid knowledge of medicinal plants, cannabis, medicinal plants, and fundi. Combined with years of personal studies in molecular biology, it is sure that Ethan will be able to lead the company toward success. Mr. Styles will use “multiple genomic data platforms to cross reference client-specific data against historical and current genomic patterns” to make direct recommendations regarding appropriate active ingredients.
“It gives me great pleasure to have Mr. Styles join our corporate team. While getting to know Ethan for the last year and a half, I experienced first hand his extensive knowledge of therapeutic plants and fungi. I learned from him what really matters when it comes to personalized health and wellness. He has been the missing link we were looking for in the production of nutraceutical whole plant and fungi-based human support product development, utilizing molecular biology and genomic based sciences”
Peter Wojcik, CEO of Pharmagreen.
Regarding market cap, the company’s is still incredibly low. It is currently valued at around $3M for a stock price worth $0.0066. The stock price witnessed a 52-week high of $0.03 for a 52-week low of $0.004. You understood it. The stock is strongly undervalued, considering all the great news Pharmagreen Biotech shared and the two significant markets in which the company is involved. It is fair and not biased to state the proper stock price valuation could significantly be higher than its 52-week high. Despite the positive news, the stock currently gave a -67% YoY return on investment.
What should you remember?
Pharmagreen Biotech (OTC: PHBI) is involved in two sectors with a high growth opportunity. Cannabis is expected to have a CAGR of 25%, and nutraceuticals should witness a CAGR of 5%. Given the recent addition of Ethan Styles to the board, and the near-term revenue, Pharmagreen Biotech solidly hints to us that it could be the “10 bagger” you are looking for.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
All Articles
The latest
Alset Capital Inc. (TSXV: KSUM) : Innovative Advancements Together with Nvidia
Discover The Phillips Township Property from Golden Rapture (CSE:GLDR)
NurExone Unlocks Several Milestones Since March 2024 (TSXV: NRX, FSE: J90, NRX.V)
Subscribe
©2024 10xAlerts